Inpatients diagnosed with mild to moderated COVID-19 pneumonia with aged greater than 18 years old COVID-19, ICS, pneumonia
Conditions
Interventions
Subjects with mild to moderate COVID-19 pneumonia will be treated with inhaled budesonide 800 microgram (200 microgram two puffs twice per day) plus standard usual care (SUC). The subjects will be pre
Experimental Drug,No Intervention No treatment
Inhaled budesonide group,Control group
Sponsors
Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Inpatients diagnosed with mild to moderated COVID-19 pneumonia (Infiltration in CXR and oxygen saturation (SpO2) equal or greater than 94% on room air. The CXR will be written by pulmonologists and/or radiologists at the first day of admission or the first day of perform CXR. 2. aged equal or greater than 18 years old
Exclusion criteria
Exclusion criteria: 1. COPD and asthma treated with ICS in the past 4 week 2. had recent use (within 7 days) of inhaled or systemic glucocorticoids 3. had a known allergy or contraindication to inhaled budesonide 4. subjects who have participated in the other clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severe pneumonia event 1 time measured at the day of discharge or patient turn to severe pneumonia Number of case with severe pneumonia | — |
Secondary
| Measure | Time frame |
|---|---|
| hospital length of stay 1 time at hospital discharge day | — |
Countries
Thailand
Contacts
Public ContactChaicharn Pothirat
Chiang Mai University
Outcome results
None listed